Skip to main content
. Author manuscript; available in PMC: 2023 May 15.
Published in final edited form as: Neuropharmacology. 2022 Mar 3;209:109022. doi: 10.1016/j.neuropharm.2022.109022

Figure 5: Group II mGlu receptor antagonism normalizes enhanced trace fear acquisition in MECP2Tg1/o mice.

Figure 5:

(A) Diagram illustrating the timeline of LY341495 administration prior to trace fear conditioning. Mice are treated intraperitoneally (i.p.) with vehicle (10% Tween-80) or 3mg/kg LY341495 (mGlu2/3 antagonist) 35 minutes prior to placement in the fear conditioning box. (B-C) LY341495 treatment significantly decreases the enhanced trace fear acquisition phenotype in MECP2Tg1/o mice (blue bars, vehicle: closed blue squares, n=11; LY341495: open blue squares, n=5) but not in WT littermates (white bars, vehicle: closed black circles, n=10; LY341495: open black circles, n=7). Analysis of trace period T3 (dark grey) is shown in (C). (F(9,87)=16.87; ****p<0.0001 (Vehicle: WT vs MECP2Tg1/o), ***p=0.0008 (LY341495: WT vs MECP2Tg1/o), ####p<0.0001 (MECP2Tg1/o: Vehicle vs LY341495)). 8–12-week-old mice. 2-way ANOVA with Tukey’s post-hoc test. *between-genotypes. #within-genotypes. ***p<0.001, ****p<0.0001, ####p<0.0001.